Usage of Spirometry in Managing IgG Therapy in CVID With Airway Disease
Recruiting · Phase 4 · NCT05193552
Conditions: Common Variable Immunodeficiency
At a glance
- Research payments reported, 2025
- $291,699
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 22
About the trial
- Sponsor
- University of Alabama at Birmingham (with CSL Behring)
- Tested
- Hizentra (drug)
- Dates
- Started 2024-01-15; completion 2027-12
- Results posted
- Not yet
Although there is evidence in the literature that gammaglobulin replacement therapy can lead to a reduction in the prevalence of pulmonary infection and improved lung function, there is no published study to guide immunologists regarding the use of spirometry in titrating IG therapy to assist in the management of immunodeficiency patients with regards to gammaglobulin replacement therapy. The investigators propose to study the use of spirometry to identify patients that could potentially benefit from an increase in IGRT. The investigators will identify 22 common variable immune deficiency (CVID) study subjects on stable IGRT replacement therapy equivalent to 0.40 to 0.60 gm/kg per 4 weeks…
From ClinicalTrials.gov, last updated 2026-05-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Csl Behring reported $291,699 in research payments for this study in 2025 (9 payments).
Products named: Hizentra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.